Anastrozole

Anastrozole is a non-steroidal aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer, primarily in postmenopausal women. It functions by selectively inhibiting the aromatase enzyme, thereby reducing estrogen biosynthesis and slowing tumor growth. The compound is supplied as a white to off-white crystalline powder, soluble in organic solvents and sparingly soluble in water.

This pharmaceutical-grade active ingredient meets stringent purity standards typical for oncology drugs, with assays usually confirming a minimum 98% active substance content. Anastrozole is commonly formulated as 1 mg oral tablets, though the raw API form allows for custom dosage preparations. It is stable under standard storage conditions, with a typical shelf life of 24 months when kept below 25°C in a dry environment.

Oncology clinics and pharmaceutical manufacturers source Anastrozole for hormone therapy regimens and compounding applications. Bulk shipments are typically packed in sealed foil bags or drums under nitrogen to prevent oxidation. Buyers should confirm packaging specifications, as exposure to moisture or light can degrade the compound. Regulatory compliance often requires certificates of analysis and GMP documentation for each batch.

Jinlan Pharm-Drugs Technology Co., Ltd. is based in Hangzhou, China, with its registered address at 1113 Modern Star, #337 Shaoxing Road. The company operates as an imported-tier supplier in the pharmaceutical sector, specializing in active pharmaceutical ingredients and oncology-related compounds.

The supplier’s profile indicates a harbor trust tier, with no recorded response activity to date. While the listing does not disclose certifications, manufacturing scale, or client details, its focus on API supply suggests alignment with B2B pharmaceutical sourcing needs. Buyers are advised to request current GMP or ISO documentation directly from the supplier for verification.